Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-10-21 01:36Core Insights - On October 20, Jiuzhou Pharmaceutical experienced a slight decline of 0.05% with a trading volume of 444 million yuan, indicating a stable market presence [1] - As of September 30, Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, which is an 18.51% increase compared to the previous year [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3] Financing and Trading Activity - On October 20, Jiuzhou Pharmaceutical had a net financing purchase of 1.664 million yuan, with a total financing balance of 528 million yuan, representing 3.14% of its market capitalization [1] - The company’s financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - In terms of securities lending, Jiuzhou Pharmaceutical had a low short-selling balance of 2.3136 million yuan, which is below the 50th percentile of the past year, suggesting limited bearish sentiment [1] Shareholder and Institutional Holdings - As of September 30, the number of Jiuzhou Pharmaceutical shareholders increased to 59,200, a rise of 10.22%, while the average number of shares held per shareholder decreased by 9.27% to 15,035 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 20.368 million shares, an increase of 7.8125 million shares from the previous period [3] - The sixth largest shareholder, China Europe Medical Health Mixed A, holds 17.403 million shares, up by 3.9767 million shares, while the seventh largest, Huabao CSI Medical ETF, reduced its holdings by 2.5629 million shares to 15.2225 million shares [3]